Impact of Fecal Microbiota Transplantation on Survival Rates in Severe Alcoholic Hepatitis Patients: A Systematic review and Meta-Analysis

Presented in 13th World Gastroenterology, IBD & Hepatology Conference in Holiday Inn Dubai, Al Barsha, UAE & Virtual from December 15-17, 2023. 

Speaker Name: Amira Mohamed Taha
Category: (Oral)
Research interest: Microbiota, Hepatology, internal medicine
Biography: Amira Mohamed Taha is a MD at Faculty of Medicine, Fayoum University. She has published more than 5 articles in peer-reviewed journals as a first authors including the LANCET ID. She has more than 5 abstracts accepted for international conferences including the American heart association.

Amira Mohamed Taha1, Abdelrahman Mohamed Mahmoud2, Khaled Abouelmagd3, 1Faculty of Medicine, Fayoum University, Fayoum, Egypt,, 2 Faculty of Medicine, Menoufia University, Menoufia, Egypt., 3Cardiology Department, Faculty of Medicine, Al-Azhar University, New Damietta, Egypt

Global Journal of Gastroenterology & Hepatology Research [GJGHR]
Visit Speaker page:

Introduction:  Severe alcoholic hepatitis (SAH) is a serious condition with few effective treatment options. Fecal Microbiota Transplantation (FMT) has been proposed to treat SAH by modulating the gut-liver axis. The purpose of this meta-analysis was to compare the efficacy of FMT versus the standard of care (SOC) in improving SAH patient survival rates.

Methods: Up to September 2023, a thorough search of electronic databases that included PubMed, Scopus, and Web of Science was conducted. We included randomised controlled trials and observational studies comparing the survival rates of SAH patients undergoing FMT versus SOC. Using Review Manager 5.4, we pooled data to calculate odds ratios (ORs) with 95% confidence intervals (CIs).

Results: The meta-analysis consisted of six studies with a total of 371 patients. Patients who received FMT had significantly higher survival rates at 1 and 3 months compared to those who received SOC, with pooled odds ratios (OR) of 2.91 (95% CI: 1.56 – 5.42, p = 0.0008) and 2.89 (95% CI: 1.68 – 4.98, p = 0.0001), respectively. However, the survival advantage disappeared after 6-12 months of follow-up, with a pooled OR of 1.65 (95% CI: 0.50 – 5.41, p = 0.41). The heterogeneity among the included studies was found to be non-significant in terms of survival rates at 1 and 3 months (I2 = 0%, p = 0.57) and (I2 = 0%, p = 0.56), but significant in terms of survival rates at 6-12 months (I2 = 76%, p = 0.02).

Conclusion: This meta-analysis highlights the potential of FMT in significantly improving short-term survival rates in SAH patients. However, the survival benefit did not last over a longer period of 6-12 months. These findings call for additional research into the long-term efficacy and safety of FMT, along with strategies for extending the survival benefit.

Keywords:  Fecal Microbiota Transplantation, FMT, Survival, Severe Alcoholic Hepatitis, Meta-analysis.

Digital Formats:

Crohn’s and Colitis Journals | Gastroenterology & Hepatology Journals | Gastroenterology Journals | Research Gastroenterology and Hepatology Journals | Clinical and Experimental Gastroenterology Journals | Gastrointestinal Endoscopy Journals | Therapeutic Advances in Gastroenterology Journals | Colorectal Disease: clinical and molecular gastroenterology and surgery Journals | Inflammatory Bowel Diseases Journals | Expert Review of Gastroenterology & Hepatology Journals | Clinical Colorectal Journals | Cancer Gut Journals | Endoscopy Journals | Hepatitis B Annual Journals | Hepato-biliary-Pancreatic Sciences Journals | Medical Bulletin Journals 

Upcoming Conference:

14th World Gastroenterology, IBD & Hepatology Conference
Visit here:
Submit your abstract/research paper here:
Attend as a Speaker/Poster/Delegate In-person kindly register here:
Attend as a Speaker/Poster/Delegate virtually kindly register here:


Back to top button